The burden of illness of cancer: economic cost and quality of life.

Cancer is a major public health issue and represents a significant burden of disease. In this chapter, we analyze the main measures of burden of disease as relate to cancer. Specifically, we review incidence and mortality, years of life lost from cancer, and cancer prevalence. We also discuss the economic burden of cancer, including cost of illness, phase-specific and long-term costs, and indirect costs. We then examine the impact of cancer on health-related quality of life as measured in global terms (disability-adjusted life years and quality-adjusted life years) and using evaluation-oriented applications of health-related quality of life scales. Throughout, we note the relative strengths and weaknesses of the various approaches to measuring the burden of cancer as well as the methodologic challenges that persist in burden-of-illness research. We conclude with a discussion of the research agenda to improve our understanding of the burden of cancer and of illness more generally.

[1]  M. Baily,et al.  Health Care Productivity , 1997 .

[2]  D. Cutler,et al.  Measuring the Health of the U.S. Population , 1997 .

[3]  D. Fryback,et al.  Toward consistency in cost-utility analyses: using national measures to create condition-specific values. , 1998, Medical care.

[4]  N Urban,et al.  Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. , 1995, Journal of the National Cancer Institute.

[5]  N. Powe,et al.  The relation between funding by the National Institutes of Health and the burden of disease. , 1999, The New England journal of medicine.

[6]  P. Romano,et al.  Folic acid fortification of grain: an economic analysis. , 1995, American journal of public health.

[7]  P. Erickson,et al.  Years of healthy life. , 1995, Healthy People 2000 statistical notes.

[8]  C. Somkin,et al.  Cost of Care for Cancer in a Health Maintenance Organization , 1997, Health care financing review.

[9]  T. Hodgson,et al.  Medical Expenditures for Major Diseases, 1995 , 1999, Health care financing review.

[10]  I. Thompson,et al.  Profile of men randomized to the prostate cancer prevention trial: baseline health-related quality of life, urinary and sexual functioning, and health behaviors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  B A Miller,et al.  The role of increasing detection in the rising incidence of prostate cancer. , 1995, JAMA.

[12]  A. Williams,et al.  Calculating the global burden of disease: time for a strategic reappraisal? , 1999, Health economics.

[13]  L. Kessler,et al.  Potential for Cancer Related Health Services Research Using a Linked Medicare‐Tumor Registry Database , 1993, Medical care.

[14]  Problems in Measuring the Cost of Illness , 1982, Evaluation & the health professions.

[15]  Dorothy P. Rice,et al.  The economic costs of illness: A replication and update , 1985, Health care financing review.

[16]  N. Neymark.  The Economic Burden of Cancer , 1998 .

[17]  D. Cella,et al.  The Functional Assessment of Cancer Therapy (FACT) and Functional Assessment of HIV Infection (FAHI) quality of life measurement system , 1996 .

[18]  D. Osoba.  What has been learned from measuring health-related quality of life in clinical oncology. , 1999, European journal of cancer.

[19]  M. Weinstein,et al.  Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men. , 2000, The American journal of medicine.

[20]  B. Given,et al.  Family and out-of-pocket costs for women with breast cancer. , 1994, Cancer practice.

[21]  Alan D. Lopez,et al.  Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study , 1997, The Lancet.

[22]  D. Osoba,et al.  Health-related quality of life in women with metastatic breast cancer treated with trastuzumab (Herceptin). , 1999, Seminars in oncology.

[23]  R D Etzioni,et al.  Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. , 1999, Medical care.

[24]  D. Whynes,et al.  Cost-effectiveness of screening for colorectal cancer: a simulation model. , 1995, IMA journal of mathematics applied in medicine and biology.

[25]  L. Kessler,et al.  Medicare Payments from Diagnosis to Death for Elderly Cancer Patients by Stage at Diagnosis , 1995, Medical care.

[26]  N K Aaronson,et al.  Quality of life assessment in daily clinical oncology practice: a feasibility study. , 1998, European journal of cancer.

[27]  J. Norum.  Adjuvant Cyclophosphamide, Methotrexate, Fluorouracil (CMF) in Breast Cancer: Is it Cost-effective? , 2000, Acta oncologica.

[28]  D. Osoba,et al.  Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  D. Osoba,et al.  Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. , 1997, European journal of cancer.

[30]  M. Essink‐bot,et al.  A national burden of disease calculation: Dutch disability-adjusted life-years. Dutch Burden of Disease Group. , 2000, American journal of public health.